drugset / Trial / NCT01810380

Brexpiprazole in Patients With Acute Schizophrenia

NCT01810380

RandomizedParallel-groupDouble-blindTreatment

Summary

To determine the efficacy and safety of brexpiprazole for the treatment of adults experiencing an acute episode of schizophrenia.

Timeline

Start
2013-03
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Brexpiprazole Small molecule 2 mg
Subject Brexpiprazole Small molecule 3 mg
Subject Brexpiprazole Small molecule 4 mg
Subject Quetiapine Small molecule 400 mg
Subject Quetiapine Small molecule 600 mg
Subject Quetiapine Small molecule 800 mg

Indications